Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure

Exclusion Criteria

• •Severe comorbidity with life expectancy \<3 months according to investigators assessment
• •Currently receiving extracorporeal membrane oxygenation (ECMO)
• •Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia
• •Patients with diagnosed significant pulmonary embolism or deep vein thrombosis in the previous 3 months
• •Patients who have been intubated for more than 48 hours
• •Known hypersensitivity to dimethyl sulfoxide (DMSO) or to porcine or bovine proteins
• •Acute co-morbidity within 7 days before inclusion such as stroke
• •History of severe chronic history of heart disease, recent myocardial infarction or unstable angina, lung disease (requiring home oxygen), pulmonary hypertension, or liver comorbidities
• •Malignancy that requires treatment in the previous two years (excluding non-melanoma skin malignancies treated by excision, or cryotherapy)
• •History of immunosuppression (immunomodulators or anti-rejection drugs in past year, or active disease, autoimmune disease on treatment, transplant recipients) or anaphylaxis
• •Refusal of blood products
• •Severe co-morbidity/co-morbidities which in the opinion of the investigators would compromise safety assessments
• •Pregnant or breast-feeding
• •Actively participating on another trial of an investigational agent for ARDS
• •Unacceptable laboratory blood tests for alanine aminotransferase (ALT)/aspartate aminotransferase (AST), neutrophils, or platelets